{"id":"NCT02600559","sponsor":"Otonomy, Inc.","briefTitle":"Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes","officialTitle":"An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2015-11-09","resultsPosted":"2020-09-22","lastUpdate":"2020-10-19"},"enrollment":501,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Otitis Media"],"interventions":[{"type":"DRUG","name":"OTO-201 (ciprofloxacin)","otherNames":["OTIPRIO"]}],"arms":[{"label":"0.1 mL OTO-201","type":"EXPERIMENTAL"}],"summary":"This is an 8-week, multicenter, open-label study in which eligible subjects with a history of otitis media requiring TT placement will receive 6 mg OTO-201 to each ear. The study is designed to evaluate the safety and efficacy of OTO-201 in subjects undergoing TT placement with common concurrent surgeries and any middle ear effusion status.","primaryOutcome":{"measure":"Number of Subjects With Post-surgical Otorrhea","timeFrame":"Week 4","effectByArm":[{"arm":"6 mg OTO-201","deltaMin":383,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":501},"commonTop":["Device occlusion","Pyrexia","Upper Respiratory Infection","Ear Pain","Rhinorrhea"]}}